tiprankstipranks
Advertisement
Advertisement
OnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst
PremiumRatingsOnKure Therapeutics: Positive View on OKI-219 Ahead of PIKture-1 Breast Cancer Data as Key Upside Catalyst
2M ago
OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
Premium
The Fly
OnKure Therapeutics price target lowered to $27 from $34 at H.C. Wainwright
2M ago
OnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)
Premium
The Fly
OnKure Therapeutics reports Q4 EPS (99c), consensus ($1.15)
2M ago
Buy Recommendation for OnKure Therapeutics Based on Strategic Development of PI3Kα Programs and Promising OKI-219 Trial Results
PremiumRatingsBuy Recommendation for OnKure Therapeutics Based on Strategic Development of PI3Kα Programs and Promising OKI-219 Trial Results
8M ago
OnKure Therapeutics Advances Cancer Drug Development
Premium
Company Announcements
OnKure Therapeutics Advances Cancer Drug Development
9M ago
OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)
Premium
The Fly
OnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100